Abstract
Respiratory syncytial virus (RSV) causes lower respiratory tract infections and hospitalization in children under five years of age, with a higher risk of severe disease among preterm infants and patients with cardiopulmonary comorbidities. Palivizumab reduces RSV-associated hospitalizations in high-risk pediatric populations; however, its effectiveness may depend on adherence to and timely administration of the prophylactic regimen. The objective was to evaluate the association between adherence to palivizumab prophylaxis and respiratory outcomes during the six months following the first dose, with respiratory hospitalization considered the primary outcome. A quantitative, observational, analytical, longitudinal, retrospective cohort study was conducted using census sampling. Fifty patients treated between 2023 and 2026 were included, six (12.0%) with complete and timely prophylaxis and 44 (88.0%) with incomplete or untimely prophylaxis. For the primary outcome, 49 patients were evaluable. Respiratory hospitalization occurred in 0/6 patients (0%) with complete and timely prophylaxis and in 13/43 (30.2%) with incomplete or untimely prophylaxis; the difference did not reach statistical significance (p = 0.175). A lower frequency of respiratory hospitalization was observed in the complete and timely prophylaxis group, although this finding should be interpreted with caution because of the small sample size.
References
Berry, J. G., Toomey, S. L., Zaslavsky, A. M., Jha, A. K., Nakamura, M. M., Klein, D. J., Feng, J. Y., Shulman, S., Chiang, V. W., Kaplan, W., Hall, M., & Schuster, M. A. (2013). Pediatric readmission prevalence and variability across hospitals. JAMA, 309(4), 372–380.https://doi.org/10.1001/jama.2012.188351
Castillo, L. M., Bugarin, G., Arias, J. C., Barajas Rangel, J. I., Serra, M. E., & Vain, N. (2017). One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America. Jornal de Pediatria, 93(5), 467–474. https://doi.org/10.1016/j.jped.2016.11.006
Chow, J. W., Chicella, M. F., Christensen, A. M., Moneymaker, C. S., Harrington, J., & Dice, J. E. (2017). Improving palivizumab compliance through a pharmacist-managed RSV prevention clinic. Journal of Pediatric Pharmacology and Therapeutics, 22(5), 338–343. https://doi.org/10.5863/1551-6776-22.5.338
Feitosa, D. C., & Vieira, S. E. (2025). Challenges in the prophylaxis of severe respiratory syncytial virus infections. Jornal de Pediatria, 101(5), 101405. https://doi.org/10.1016/j.jped.2025.04.003
Fitzpatrick, T., McNally, J. D., Stukel, T. A., Kwong, J. C., Wilton, A. S., Fisman, D., & Guttmann, A. (2021). Palivizumab’s real-world effectiveness: A population-based study in Ontario, Canada, 1993–2017. Archives of Disease in Childhood, 106(2), 173–179. https://doi.org/10.1136/archdischild-2020-319472
Galvis, C., Colmenares, A., Cabrales, L., Ibatá, L., Marulanda, J., Ovalle, O., Puello, D., Rojas, C., Africano, M., Ballesteros, A., & Posso, H. (2022). Impact of immunoprophylaxis with palivizumab on respiratory syncytial virus infection in preterm infants less than 35 weeks in Colombian hospitals. Pediatric Pulmonology, 57(10), 2420–2427. https://doi.org/10.1002/ppul.26051
Gilca, R., Billard, M.-N., Zafack, J., Papenburg, J., Boucher, F. D., Charest, H., Rochette, M., & De Serres, G. (2020). Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada. Preventive Medicine Reports, 20, 101180. https://doi.org/10.1016/j.pmedr.2020.101180
Gonzales, T., Bergamasco, A., Cristarella, T., Goyer, C., Wojdyla, M., Oladapo, A., Sawicky, J., Yee, J., & Moride, Y. (2024). Effectiveness and safety of palivizumab for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus: A systematic review. American Journal of Perinatology, 41(Suppl. 1), e1107–e1115. https://doi.org/10.1055/a-1990-2633
Hui, C., Paes, B., Papenburg, J., Mitchell, I., Li, A., Lanctôt, K. L., & CARESS Investigators. (2016). Palivizumab adherence and outcomes in Canadian Aboriginal children. Pediatric Infectious Disease Journal, 35(11), 1187–1193. https://doi.org/10.1097/INF.0000000000001282
Krilov, L. R., & Anderson, E. J. (2020). Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics. Journal of Perinatology, 40(8), 1135–1144. https://doi.org/10.1038/s41372-020-0689-y
Kuitunen, I., Backman, K., Gårdström, E., & Renko, M. (2024). Monoclonal antibody therapies in respiratory syncytial virus prophylaxis—An umbrella review. Pediatric Pulmonology, 59(10), 2374–2380. https://doi.org/10.1002/ppul.27041
Li, Y., Wang, X., Blau, D. M., Caballero, M. T., Feikin, D. R., Gill, C. J., Madhi, S. A., Omer, S. B., Simões, E. A. F., Campbell, H., Bermejo Pariente, A., Bardach, D., Bassat, Q., Casalegno, J.-S., Chakhunashvili, G., Crawford, N., Danilenko, D., Do, L. A. H., Echavarria, M., … Nair, H. (2022). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis. The Lancet, 399(10340), 2047–2064. https://doi.org/10.1016/S0140-6736(22)00478-0
Mitchell, I., Li, A., Bjornson, C. L., Lanctôt, K. L., Paes, B. A., & CARESS Investigators. (2022). Respiratory syncytial virus immunoprophylaxis with palivizumab: 12-year observational study of usage and outcomes in Canada. American Journal of Perinatology, 39(15), 1668–1677. https://doi.org/10.1055/s-0041-1725146
Moreno-Espinosa, S., Estrada-Ruelas, I., Sánchez-Miranda, Y., Flores-Arizmendi, R. A., Macías-Avilés, H. A., Ruiz-Gutiérrez, H. H., Lima-Rogel, V., Gutiérrez-Padilla, J. A., & González-Gómez, L. A. (2020). Prevención de la infección grave por virus sincicial respiratorio en la población pediátrica en México: Postura de un grupo de expertos. Boletín Médico del Hospital Infantil de México, 77(3), 100–111. https://doi.org/10.24875/BMHIM.19000166
Ortiz, C., Vásquez, I., Zamorano, A., D’Apremont, I., Pittaluga, E., Díaz, M., & Campos, C. (2024). Beneficios de la administración domiciliaria de palivizumab en grupos de alto riesgo. Andes Pediatrica, 95(4), 423–429. https://doi.org/10.32641/andespediatr.v95i4.4943
Ortiz Ibarra, F. J., González Saldaña, N., Arias de la Garza, E., Castillo Bejarano, J. I., Gutiérrez Tobar, I. F., Laris González, A., Lima Rangel, M. V., Martínez Medina, L., Moreno Espinosa, S., Ochoa Pérez, U., Ordoñez Ortega, J., Ortiz Casas, B., Revelo Castro, O., Tamez Rivera, O., Tena Alavez, G., Vázquez Rivera, M., Villa Guillen, M., & Otero Mendoza, F. (2024). Consenso de la Asociación Mexicana de Infectología Pediátrica (AMIP): Prevención de la infección por virus sincitial respiratorio en México, 2024. Revista Latinoamericana de Infectología Pediátrica, 37(Supl. 1), s6–s28. https://doi.org/10.35366/118344
Resch, B. (2017). Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Human Vaccines & Immunotherapeutics, 13(9), 2138–2149. https://doi.org/10.1080/21645515.2017.1337614
Sierra, C. M., Park, A., Eum, E., Garcia, G., Lopez, M., Daniel, S. N., Bahjri, K., & Parbuoni, K. A. (2021). Adherence to the 2014 American Academy of Pediatrics palivizumab prophylaxis recommendations. Pediatric Pulmonology, 56(5), 1121–1126. https://doi.org/10.1002/ppul.25225
Stiboy, E., Chan, M., Islam, M. S., Saravanos, G. L., Lui, K., Jaffe, A., & Homaira, N. (2023). Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral disease in high-risk infants. Pediatric Pulmonology, 58(4), 1210–1220. https://doi.org/10.1002/ppul.26324
Stockton, W., Chen, Y., Jun, A., Lee, T., Murphy, M. C., & Magedman, G. (2018). Initial palivizumab dose administration in outpatient clinic after hospital discharge. Pediatric Infectious Disease Journal, 37(11), 1124–1129. https://doi.org/10.1097/INF.0000000000001999
Wang, D. Y., Li, A., Paes, B., Mitchell, I., Lanctôt, K. L., & CARESS Investigators. (2017). First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005–2015). European Journal of Pediatrics, 176(3), 413–422. https://doi.org/10.1007/s00431-017-2849-4
Wang, X., Li, Y., Shi, T., Bont, L. J., Chu, H. Y., Zar, H. J., Wahi-Singh, B., Ma, Y., Cong, B., Sharland, E., Riley, R. D., Deng, J., Figueras-Aloy, J., Heikkinen, T., Jones, M. H., Liese, J. G., Markić, J., Mejias, A., Nunes, M. C., … Nair, H. (2024). Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: A systematic review and meta-analysis of aggregated and individual participant data. The Lancet, 403(10433), 1241–1253. https://doi.org/10.1016/S0140-6736(24)00138-7
Wilkins, D., Wählby Hamrén, U., Chang, Y., Clegg, L. E., Domachowske, J., Englund, J. A., Muller, W. J., Leach, A., Kelly, E. J., & Villafana, T. (2024). RSV neutralizing antibodies following nirsevimab and palivizumab dosing. Pediatrics, 154(5), e2024067174. https://doi.org/10.1542/peds.2024-067174
Wong, S. K., Li, A., Lanctôt, K. L., & Paes, B. (2018). Adherence and outcomes: A systematic review of palivizumab utilization. Expert Review of Respiratory Medicine, 12(1), 27–42. https://doi.org/10.1080/17476348.2018.1401926
Yeo, K. T., Yung, C. F., Khoo, P. C., Saffari, S. E., Sng, J. S. P., How, M. S., & Quek, B. H. (2021). Effectiveness of palivizumab against respiratory syncytial virus hospitalization among preterm infants in a setting with year-round circulation. Journal of Infectious Diseases, 224(2), 279–287. https://doi.org/10.1093/infdis/jiaa749

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 Alexia Paola Leyva Ramírez, Eduardo Herrera López
